Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., … Smith, B. D. (2009). Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse. In BLOOD (Vol. 114, pp. 325–326). New Orleans, LA: AMER SOC HEMATOLOGY.

Levis, Mark, Farhad Ravandi, Eunice S. Wang, Maria R. Baer, Alexander Perl, Steven Coutre, Harry Erba, et al. “Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.” In BLOOD, 114:325–26. AMER SOC HEMATOLOGY, 2009.

Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, et al. Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse. In: BLOOD. AMER SOC HEMATOLOGY; 2009. p. 325–6.

Levis, Mark, et al. “Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.” BLOOD, vol. 114, no. 22, AMER SOC HEMATOLOGY, 2009, pp. 325–26.

Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Jedrzejczak WW, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse. BLOOD. AMER SOC HEMATOLOGY; 2009. p. 325–326.